NCT05935085

This Study Will Evaluate the Safety, Tolerability, and Efficacy of ANB032 in Subjects with Moderate to Severe Atopic Dermatitis (AD).

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of ANB032 in the Treatment of Subjects with Moderate to Severe Atopic Dermatitis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 201 (actual)
• Sponsor: AnaptysBio, Inc. · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study will evaluate the safety, tolerability, and efficacy of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Detailed description

This is a Phase 2, randomized, double blind, placebo controlled, parallel group, multicenter study to evaluate the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of ANB032 in subjects with moderate to severe atopic dermatitis (AD).

Conditions

• Atopic Dermatitis Eczema

Interventions

Type	Name	Description
DRUG	ANB032	BTLA agonist antibody
DRUG	Placebo	Placebo

Timeline

• Start date: 2023-06-13
• Primary completion: 2024-10-16
• Completion: 2025-01-07
• First posted: 2023-07-07
• Last updated: 2025-02-14

Locations

78 sites across 7 countries: United States, Australia, Canada, Czechia, Georgia, New Zealand, Poland

Regulatory

• FDA-regulated drug study